Treace Medical cuts FY25 revenue view to $211M-$213M from $224M-$230M

Consensus $227.17M. The company said, “The Company is revising full-year 2025 revenue guidance to $211 million to $213 million representing growth of 1% to 2% compared to full-year 2024. This compares to previous guidance of $224 million to $230 million. The Company now expects a loss in Adjusted EBITDA in the range of $6.5 million to $7.5 million for full year 2025 compared to previous guidance of breakeven Adjusted EBITDA for the full-year 2025. This reflects a 32% to 41% improvement over the prior year. The Company’s reduction in full-year 2025 guidance is primarily a result of expected lower sales from its flagship Lapiplasty System, largely due to evolving surgeon preferences for minimally invasive osteotomy procedures, competition, lower patient demand for elective bunion surgery due to macroeconomic conditions and the other headwinds described above.”